Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

@article{Pavn2006AntiobesityEO,
  title={Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.},
  author={Francisco Javier Pav{\'o}n and Ainhoa Bilbao and Laura Hern{\'a}ndez-Folgado and Andrea Cippitelli and Nadine Jagerovic and Gumersindo Abell{\'a}n and Mar{\'i}a Isabel Rodr{\'i}guez-Franco and Antonia Serrano and Manuel Mac{\'i}as and Raquel G{\'o}mez and M Fabregat Navarro and Pilar Goya and Fernando Rodr{\'i}guez de Fonseca},
  journal={Neuropharmacology},
  year={2006},
  volume={51 2},
  pages={358-66}
}
The present study evaluates the pharmacological profile of the new neutral cannabinoid CB1 receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole -LH-21- on feeding behavior and alcohol self-administration in rats, two behaviors inhibited by cannabinoid CB1 receptor antagonists. Administration of LH-21 (0.03, 0.3 and 3 mg/kg) to food-deprived rats resulted in a dose-dependent inhibition of feeding. Subchronic administration of LH-21 reduced food intake and body… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…